10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

23, 2025 /PRNewswire/ -- At the Advances in Genome Biology and Technology (AGBT) General Meeting, 10x Genomics ... full control and flexibility over how they design and scale their studies.

The market expects 10x Genomics (TXG) to deliver a year-over ... On the other hand, if they miss, the stock may move lower. While the sustainability of the immediate price change and future ...

Q4 2024 Earnings Call Transcript February 12, 2025 10x Genomics, Inc. misses on earnings expectations. Reported EPS is $-0.4 EPS, expectations were $-0.29. Operator: Thank you for standing by. My name ...

23, 2025 /PRNewswire/ -- At the Advances in Genome Biology and Technology (AGBT) General Meeting, 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and ... giving researchers full control and ...

Biotechnology company 10x Genomics and Harvard University reached a Feb. 6 settlement in a patent lawsuit that they jointly filed against Vizgen Inc. in 2022, alleging that Vizgen unlawfully used ...

Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. 10x Genomics doesn't appear a compelling earnings-beat candidate. However ...

18, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq ... We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research ...

10X Genomics reported a Q4 2024 EPS of -$0.40, below the forecast of -$0.31. Revenue for the quarter was $165 million, exceeding expectations but down 10% year-over-year. The stock dropped 6.75% in ...